Profile data is unavailable for this security.
About the company
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
- Revenue in USD (TTM)1.56bn
- Net income in USD-6.54m
- Incorporated1989
- Employees3.95k
- LocationIntegra Lifesciences Holdings Corp1100 Campus RoadPRINCETON 08540United StatesUSA
- Phone+1 (609) 275-0500
- Fax+1 (609) 750-4277
- Websitehttps://www.integralife.com/
More ▼
Mergers & acquisitions
| Acquired company | IART:NSQ since announced | Transaction value |
|---|---|---|
| Acclarent Inc | -42.38% | 280.00m |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STAAR Surgical Co | 341.22m | 21.78m | 1.31bn | 1.06k | 60.90 | 3.07 | 47.53 | 3.85 | 0.4381 | 0.4381 | 6.90 | 8.69 | 0.6763 | 2.03 | 3.15 | 323,128.80 | 4.32 | 6.77 | 4.92 | 7.90 | 78.73 | 76.89 | 6.38 | 9.16 | 5.38 | -- | 0.0002 | 0.00 | 13.37 | 21.07 | -46.18 | 33.85 | 51.95 | -- |
| Adapthealth Corp | 3.26bn | -217.76m | 1.33bn | 10.70k | -- | 0.8744 | 8.05 | 0.4064 | -1.64 | -1.64 | 24.23 | 11.27 | 0.7096 | 21.15 | 8.45 | 304,912.50 | -4.57 | -4.34 | -5.14 | -4.89 | 19.03 | 18.28 | -6.44 | -6.47 | 0.9951 | 2.29 | 0.5757 | -- | 7.73 | -- | -1,169.99 | -- | -- | -- |
| Myriad Genetics, Inc. | 823.60m | -116.00m | 1.41bn | 2.70k | -- | 1.93 | -- | 1.71 | -1.30 | -1.30 | 9.21 | 8.04 | 0.7385 | 9.91 | 6.84 | 305,037.00 | -10.40 | -- | -12.43 | -- | 69.15 | -- | -14.08 | -- | 1.73 | -105.00 | 0.0506 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Alphatec Holdings Inc | 572.74m | -177.87m | 1.43bn | 839.00 | -- | -- | -- | 2.49 | -1.27 | -1.27 | 4.08 | 0.1546 | 0.8089 | 1.11 | 7.73 | 682,644.80 | -25.12 | -30.97 | -32.00 | -39.47 | 69.47 | 66.02 | -31.06 | -46.22 | 1.15 | -3.66 | 0.9596 | -- | 37.45 | 39.38 | -23.36 | -- | 67.92 | -- |
| Inmode Ltd | 423.75m | 153.67m | 1.45bn | 581.00 | 10.30 | 2.13 | 9.40 | 3.42 | 1.85 | 1.85 | 5.04 | 8.92 | 0.5239 | 1.58 | 10.15 | 729,339.10 | 19.00 | 31.32 | 20.77 | 35.64 | 81.64 | 84.46 | 36.26 | 39.65 | 9.91 | -- | 0.00 | 0.00 | 8.32 | 37.49 | 22.54 | 54.65 | 13.10 | -- |
| 10X Genomics Inc | 629.74m | -182.55m | 1.73bn | 1.26k | -- | 2.40 | -- | 2.75 | -1.53 | -1.53 | 5.26 | 5.97 | 0.6677 | 2.40 | 6.72 | 500,193.00 | -19.36 | -25.52 | -21.99 | -29.05 | 66.63 | 75.88 | -28.99 | -48.53 | 4.12 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| AtriCure Inc | 447.57m | -38.92m | 1.74bn | 1.20k | -- | 3.75 | -- | 3.89 | -0.8322 | -0.8322 | 9.56 | 9.54 | 0.7365 | 1.63 | 8.41 | 372,977.50 | -6.40 | -3.72 | -7.35 | -4.10 | 74.79 | 74.36 | -8.70 | -7.64 | 2.59 | -13.76 | 0.1194 | -- | 20.84 | 14.64 | 34.49 | -- | 46.56 | -- |
| Patterson Companies, Inc. | 6.53bn | 168.41m | 1.80bn | 7.60k | 11.18 | 1.89 | 6.99 | 0.276 | 1.83 | 1.83 | 71.22 | 10.80 | 2.27 | 5.86 | 15.35 | 859,640.70 | 5.84 | 1.13 | 10.15 | 1.81 | 21.03 | 20.98 | 2.57 | 0.5157 | 0.6723 | 7.91 | 0.4474 | 304.75 | 1.50 | 3.34 | -10.42 | 18.10 | 2.17 | 0.00 |
| Rxsight Inc | 128.29m | -30.69m | 1.81bn | 374.00 | -- | 6.51 | -- | 14.08 | -0.8194 | -0.8194 | 3.40 | 6.89 | 0.5212 | 1.99 | 6.32 | 343,029.40 | -12.47 | -- | -13.62 | -- | 68.44 | -- | -23.92 | -- | 11.71 | -- | 0.0005 | -- | 81.77 | -- | 27.19 | -- | -- | -- |
| Integra Lifesciences Holdings Corp | 1.56bn | -6.54m | 1.82bn | 3.95k | -- | 1.20 | 14.24 | 1.16 | -0.0881 | -0.0881 | 20.22 | 19.73 | 0.401 | 1.59 | 5.99 | 396,583.90 | -0.1677 | 3.33 | -0.2002 | 3.68 | 59.29 | 63.67 | -0.4182 | 7.99 | 0.7261 | 4.05 | 0.5428 | 0.00 | -1.03 | 0.9219 | -62.48 | 2.19 | -2.97 | -- |
| Novocure Ltd | 577.74m | -149.78m | 1.92bn | 1.45k | -- | 5.31 | -- | 3.32 | -1.39 | -1.39 | 5.37 | 3.34 | 0.4879 | 3.59 | 8.74 | 397,617.30 | -12.65 | -7.74 | -20.29 | -8.95 | 76.42 | 77.22 | -25.93 | -14.69 | 1.44 | -- | 0.6446 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Tandem Diabetes Care Inc | 854.35m | -126.78m | 2.02bn | 2.40k | -- | 8.51 | -- | 2.37 | -1.94 | -1.94 | 13.08 | 3.62 | 0.9004 | 2.90 | 8.23 | 355,979.60 | -13.36 | -10.08 | -17.47 | -12.23 | 49.79 | 51.77 | -14.84 | -11.59 | 2.32 | -- | 0.5945 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Omnicell Inc | 1.06bn | -17.69m | 2.12bn | 3.66k | -- | 1.72 | 31.88 | 1.99 | -0.3917 | -0.3917 | 23.17 | 26.59 | 0.4704 | 5.90 | 4.06 | 291,563.30 | -0.7817 | 1.73 | -1.11 | 2.25 | 41.44 | 46.69 | -1.66 | 2.92 | 0.9529 | -- | 0.3172 | 0.00 | -11.48 | 7.82 | -460.68 | -- | 0.235 | -- |
| Premier Inc | 1.28bn | 147.17m | 2.20bn | 2.90k | 16.53 | 1.14 | 8.36 | 1.72 | 1.38 | 1.37 | 11.65 | 19.98 | 0.3562 | -- | 2.99 | 439,914.10 | 3.83 | 7.08 | 4.78 | 8.95 | 67.24 | 61.29 | 10.76 | 16.05 | -- | -- | 0.2771 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| Conmed Corp | 1.29bn | 131.74m | 2.31bn | 4.00k | 17.72 | 2.48 | 11.37 | 1.80 | 4.23 | 4.23 | 41.38 | 30.21 | 0.555 | 1.71 | 5.58 | 322,029.00 | 5.68 | 0.8972 | 6.62 | 1.02 | 55.65 | 54.95 | 10.23 | 1.65 | 1.06 | 5.22 | 0.5021 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| Irhythm Technologies Inc | 560.03m | -150.66m | 2.32bn | 2.00k | -- | 32.26 | -- | 4.14 | -4.85 | -4.85 | 18.04 | 2.29 | 0.83 | 12.56 | 8.79 | 280,012.50 | -22.33 | -21.92 | -26.27 | -26.77 | 67.83 | 69.39 | -26.90 | -25.75 | 6.12 | -24.18 | 0.90 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
Data as of Nov 22 2024. Currency figures normalised to Integra Lifesciences Holdings Corp's reporting currency: US Dollar USD
50.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 9.95m | 12.83% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 7.58m | 9.77% |
| Fuller & Thaler Asset Management, Inc.as of 30 Sep 2024 | 3.97m | 5.11% |
| AllianceBernstein LPas of 30 Sep 2024 | 3.02m | 3.90% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.83m | 3.64% |
| Boston Management & Researchas of 30 Sep 2024 | 2.74m | 3.53% |
| Sachem Head Capital Management LPas of 30 Sep 2024 | 2.43m | 3.13% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 2.24m | 2.89% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 2.08m | 2.69% |
| GMT Capital Corp.as of 30 Sep 2024 | 2.00m | 2.58% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
